VA PUGET SOUND HEALTH CARE SYSTEM

Semaglutide 2.4 mg Reduces Hospital Admissions in SELECT Trial for CVD Patients with Obesity

7 months ago

• A new analysis of the SELECT trial reveals that semaglutide 2.4 mg significantly reduces hospital admissions in adults with heart disease and obesity. • The study showed a lower percentage of patients on semaglutide 2.4 mg experienced a first hospital admission compared to placebo (33.4% vs 36.7%). • Semaglutide 2.4 mg also reduced the overall time spent in the hospital, addressing healthcare costs and quality for cardiovascular disease patients. • These findings highlight semaglutide's potential beyond cardiovascular risk reduction, impacting hospitalization rates and healthcare resource utilization.